Article
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 May 2022
Jeffers Michael, Kappeler Christian, Kuss Iris, Beckmann Georg, Mehnert Daniel H, Fredebohm Johannes, Teufel Michael
Abstract excerpt
BACKGROUND: In the phase 3 GRID trial, regorafenib improved progression-free survival (PFS) independent of KIT mutations in exons 9 and 11. In this retrospective, exploratory analysis of the GRID trial, we investigated whether a more comprehensive KIT mutation analysis could identify mutations that impact treatment outcome with regorafenib and a regorafenib-induced mutation pattern. METHODS: Archived tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.